NHS England published Commissioning Intensions for 2015/2016 for specialized services. Changes are related to reimbursement of so-called excluded medical device (including establishment of national reference price for implantable cardiac devices, bone anchored hearing devices and TAVI, and role of recommendations of NICE), provision of stereotactic surgery, genetic testing, long-term ventilation, radiotherapy and proton beam therapy, procurement of PET-CT, continuation of Evaluation through Commissioning programme, changing of commissioning for renal dialysis, bariatric surgery, specialized urology and esophageal procedures.
The deadline to submit the application for a new procedure code in Sweden is in November. This is an essential step reimbursement in many countries.
There are four areas, in which novel legislation has market access implications for medical devices.
In total, 49 evaluations of devices were performed by Spanish HTA bodies in 2013. In 61% of the evaluations economic evidence was considered, although most of reports (80%) limited their analysis to a systematic review of published economic analyses and only in 20% of cases economic analysis was performed. Industry needs to employ pro-active strategy of developing and publishing Spanish economic analysis, as it will very likely form a foundation for decision-making by HTA bodies.
In total 301 out of 573 HTAs performed in 2013-2014 for medical devices in Europe were originated from non-INAHTA members. When it comes to monitoring of HTA activity, it is relatively easy to keep track of what is going on at the level of national HTA bodies. Although, it is difficult to scale up monitoring to the level of regional/hospital HTAs. Recommendations of the later bodies may have direct and immediate impact on reimbursement/purchase policy.
Current version (v.3) of the database includes 103 studies mapping EQ-5D from another patient-reported outcomes instruments. These data can be used to estimate utility for decision-anlytic modelling for medical devices.
Conferences & Events
Meet CEO of Synergus Mattias Kyhlstedt at EUnetHTA's meeting HTA 2.0 Europe.
Meet CEO of Synergus Mattias Kyhlstedt and Senior Health Economist Oleg Borisenko at ISPOR Meeting.
Extensive overview of French national hospital database (PMSI) and its applicability for evidence generation to support market activities for medical devices companies.